Literature DB >> 15244514

Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susceptibility to esophageal and stomach cancer with smoking.

Chang-Ming Gao1, Toshiro Takezaki, Jian-Zhong Wu, Yan-Ting Liu, Jian-Hua Ding, Su-Ping Li, Ping Su, Xu Hu, Hai-Tao Kai, Zong-You Li, Keitaro Matsuo, Nobuyuki Hamajima, Haruhiko Sugimura, Kazuo Tajima.   

Abstract

Thymidylate synthetase (TS) and methylenetetrahydrofolate reductase (MTHFR) are major enzymes in the metabolism of folates, involved in DNA 'breaks', instability and hypomethylation. To investigate the possible relations between the TS 3'-UTR and MTHFR C677T polymorphisms and environmental factors impacting on risk of esophageal and stomach cancers, we conducted a case-control study in a high incidence region of China for these cancers. We recruited 138 esophageal and 155 stomach cancer cases, and 223 controls. The TS 3' -UTR and MTHFR C677T genotypes were detected by RFLP assay, using PCR products. The frequency of the -6 bp homozygous TS 3' -UTR genotype was 37.7 % in controls, higher than in Caucasians, although the present distribution was not in Hardy-Weinberg equilibrium. Ever-smoking with the -6 bp/-6 bp TS genotype elevated the ORs (2.61, 1.24-5.49; 3.54, 1.60-7.82) for cases of esophageal and stomach cancers, respectively, when compared with never-smoking with the +6 bp/+6 bp and +6 bp/-6 bp genotypes. No combination between the TS and MTHFR genotypes gave increased ORs. The present results suggest that TS polymorphism may modify the risk of esophageal and stomach cancer with smoking, pointing to the necessity for further investigations with information on folate and methionine intake with a larger population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15244514

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  7 in total

1.  Polymorphisms of thymidylate synthase in the 5'- and 3'-untranslated regions and gastric cancer.

Authors:  Wen Zhuang; Xiao-Ting Wu; Yong Zhou; Guan-Jian Liu; Tai-Xiang Wu; Xun Yao; Liang Du; Mao-Ling Wei
Journal:  Dig Dis Sci       Date:  2008-11-07       Impact factor: 3.199

2.  Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy.

Authors:  Jian-Wei Lu; Chang-Ming Gao; Jian-Zhong Wu; Hai-Xia Cao; Kazuo Tajima; Ji-Feng Feng
Journal:  J Hum Genet       Date:  2006-01-20       Impact factor: 3.172

Review 3.  Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis.

Authors:  L M Bull; D L White; M Bray; Z Nurgalieva; H B El-Serag
Journal:  Dis Esophagus       Date:  2009-02-13       Impact factor: 3.429

Review 4.  Review and pooled analysis of studies on MTHFR C677T polymorphism and esophageal cancer.

Authors:  S M Langevin; D Lin; K Matsuo; C M Gao; T Takezaki; R Z Stolzenberg-Solomon; M Vasavi; Q Hasan; E Taioli
Journal:  Toxicol Lett       Date:  2008-09-16       Impact factor: 4.372

5.  Association between polymorphisms of thymidylate synthase gene 5'- and 3'-UTR and gastric cancer risk: meta-analysis.

Authors:  Ao Mo; Yongliang Zhao; Yan Shi; Feng Qian; Yingxue Hao; Jun Chen; Shiwei Yang; Yuxing Jiang; Ziyan Luo; Peiwu Yu
Journal:  Biosci Rep       Date:  2016-12-23       Impact factor: 3.840

6.  Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.

Authors:  Xia Wang; Yadi Wang; Yue Wang; Jian Cheng; Yanyun Wang; Minwen Ha
Journal:  J Biomed Sci       Date:  2013-01-25       Impact factor: 8.410

7.  3'UTR polymorphism of Thymidylate Synthase gene increased the risk of persistence of pre-neoplastic cervical lesions.

Authors:  Nayara Nascimento Toledo Silva; Ana Carolina Silva Santos; Verlândia Mendes Nogueira; Cláudia Martins Carneiro; Angélica Alves Lima
Journal:  BMC Cancer       Date:  2020-04-15       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.